Last reviewed · How we verify

Probiotic Formula Capsule

University of Jordan · FDA-approved active Small molecule Quality 2/100

Probiotic Formula Capsule, developed by the University of Jordan, is a marketed product with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the potential for continued revenue generation until the patent expiry. The primary risk is the potential increase in competition post-2028, which could impact market share and revenue.

At a glance

Generic nameProbiotic Formula Capsule
Also known asProbiotics capsule, Probiotics supplement, lactobacillus, group 3 (Probiotic group), A mixture of Lactobacillus brevis and Lactobacillus plantarum
SponsorUniversity of Jordan
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: